Lymphoma, Mantle-Cell: all 810 studies
Page 5 of 9. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasActive, not recruitingNCT05934838Phase 1
- FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaWithdrawnNCT05934097Phase 1
- A Food Effect Study of LP-168 Tablets in Healthy SubjectsCompletedNCT05917964Phase 1
- Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Active, not recruitingNCT05878184Phase 1
- Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingNCT05864742Phase 2
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaSuspendedNCT05861050Phase 1/2
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive, not recruitingNCT05753501Phase 1
- A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaTerminatedNCT05720052Phase 1/2
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruitingNCT05716087Phase 2
- Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesCompletedNCT05694364Phase 1
- A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesActive, not recruitingNCT05665062Phase 1
- Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.TerminatedNCT05645744
- Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesTerminatedNCT05611853Phase 1/2
- A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Active, not recruitingNCT05458297Phase 2
- Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05453396Phase 2
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
- Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 YearsStatus unknownNCT05429918
- Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 YearsStatus unknownNCT05406154
- Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLTerminatedNCT05360238Phase 1/2
- Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.Active, not recruitingNCT05249959Phase 2
- Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT05214183Phase 2
- Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerApproved for marketingNCT05172700
- Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05164770Phase 3
- Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell LymphomaStatus unknownNCT05155215Phase 1/2
- Study of XL114 in Subjects With Non-Hodgkin's LymphomaTerminatedNCT05144347Phase 1
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05097443Phase 3
- A Study of OLR in First-line Treatment of Mantle Cell LymphomaStatus unknownNCT05076097Phase 2
- Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T TherapyCompletedNCT05064787Not applicable
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersActive, not recruitingNCT05020678Phase 1
- Acalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT05004064Phase 2
- PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell LymphomaWithdrawnNCT04990778Phase 2
- B-cell Chronic Lymphoid Malignancies MarkersStatus unknownNCT04952974
- Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04939272Phase 1/2
- Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT04918940Not applicable
- Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T CellsActive, not recruitingNCT04911478
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
- Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.Active, not recruitingNCT04882475
- Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH TrialCompletedNCT04872413Not applicable
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT04849715Phase 3
- RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid MalignanciesTerminatedNCT04844086Phase 1
- Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell LymphomaCompletedNCT04833504
- Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT04802590Phase 2
- Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic MalignanciesStatus unknownNCT04767308Early Phase 1
- Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
- First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesStatus unknownNCT04763083Phase 1
- A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaActive, not recruitingNCT04718883Phase 2
- Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)CompletedNCT04716075Phase 2
- Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyCompletedNCT04703686Phase 2
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTCompletedNCT04629430Not applicable
- Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCLActive, not recruitingNCT04624958Phase 2
- The Role of 18F-FDG-PET for Staging and PrognosticationCompletedNCT04600804
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04566887Phase 2
- A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for RabeprazoleCompletedNCT04564040Phase 1
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
- Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04484012Phase 2
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
- Atrial Fibrillation in Patients Receiving IbrutinibStatus unknownNCT04407845
- A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)Status unknownNCT04398953Phase 2
- TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT04323657Phase 1/2
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
- Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT04234061Phase 2
- Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell LymphomaWithdrawnNCT04231734Not applicable
- Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell LymphomaActive, not recruitingNCT04189757Phase 2
- The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological MalignanciesStatus unknownNCT04184414Early Phase 1
- Study of LUCAR-20S in Patients With R/R NHLTerminatedNCT04176913Phase 1
- Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
- Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesApproved for marketingNCT04162756
- Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)Status unknownNCT04127916
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT04115631Phase 2
- Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.Status unknownNCT04109872
- A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04082936Phase 1/2
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesActive, not recruitingNCT04072458Phase 1
- Ibrutinib for Relapsed or Refractory Mantle Cell LymphomaCompletedNCT04061850
- Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04054167Phase 2
- ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)Active, not recruitingNCT04049513Phase 1
- ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
- A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in KoreaCompletedNCT04036448
- Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaActive, not recruitingNCT04007029Phase 1
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Phase 3
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCompletedNCT03997968Phase 1/2
- Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT03946878Phase 2
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
- Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCLStatus unknownNCT03891355Phase 2
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingNCT03888105Phase 2
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesCompletedNCT03886831Phase 1